New aspects of induction chemotherapy for head and neck cancer: POSTASCO 2011.
Standard
New aspects of induction chemotherapy for head and neck cancer: POSTASCO 2011. / Mumme, Angelina; Laban, Simon; Knecht, Rainald.
In: EUR ARCH OTO-RHINO-L, Vol. 269, No. 11, 11, 2012, p. 2303-2308.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - New aspects of induction chemotherapy for head and neck cancer: POSTASCO 2011.
AU - Mumme, Angelina
AU - Laban, Simon
AU - Knecht, Rainald
PY - 2012
Y1 - 2012
N2 - Treatment options of patients with advanced head and neck cancer developed in the last years. Surgical approaches with or without radiotherapy used to be the standard therapy for a long time. Calls for organ preservation, poor overall survival and unsatisfactory quality of life made changes in this therapy regime necessary. Systemical approaches were evaluated, first concepts of platinum-based chemotherapy paired with 5-fluorouracil (PF) made up the basis of induction chemotherapy (ICT). Hypothesized advantage of this regime was improvement in local and distant tumor responsiveness with an acceptable toxicity profile. Further investigations proved the addition of docetaxel (TPF) superior to PF, which presents the gold standard of current induction chemotherapy regimes. Long-term results underlining well-known aspects of this regime as well as new approaches of induction chemotherapy were published at ASCO 2011, including the addition of bioimmunotherapy to radiotherapy, adding nanoparticle-bound albumin to chemotherapy and investigations in toxicity reduction. Further investigations are still made not only to increase survival outcomes and local control but also to improve quality of life by reducing acute and late toxicities.
AB - Treatment options of patients with advanced head and neck cancer developed in the last years. Surgical approaches with or without radiotherapy used to be the standard therapy for a long time. Calls for organ preservation, poor overall survival and unsatisfactory quality of life made changes in this therapy regime necessary. Systemical approaches were evaluated, first concepts of platinum-based chemotherapy paired with 5-fluorouracil (PF) made up the basis of induction chemotherapy (ICT). Hypothesized advantage of this regime was improvement in local and distant tumor responsiveness with an acceptable toxicity profile. Further investigations proved the addition of docetaxel (TPF) superior to PF, which presents the gold standard of current induction chemotherapy regimes. Long-term results underlining well-known aspects of this regime as well as new approaches of induction chemotherapy were published at ASCO 2011, including the addition of bioimmunotherapy to radiotherapy, adding nanoparticle-bound albumin to chemotherapy and investigations in toxicity reduction. Further investigations are still made not only to increase survival outcomes and local control but also to improve quality of life by reducing acute and late toxicities.
KW - Humans
KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
KW - Antineoplastic Agents/administration & dosage
KW - Cisplatin/administration & dosage
KW - Taxoids/administration & dosage
KW - Fluorouracil/administration & dosage
KW - Head and Neck Neoplasms/drug therapy
KW - Induction Chemotherapy/methods/trends
KW - Humans
KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
KW - Antineoplastic Agents/administration & dosage
KW - Cisplatin/administration & dosage
KW - Taxoids/administration & dosage
KW - Fluorouracil/administration & dosage
KW - Head and Neck Neoplasms/drug therapy
KW - Induction Chemotherapy/methods/trends
M3 - SCORING: Journal article
VL - 269
SP - 2303
EP - 2308
JO - EUR ARCH OTO-RHINO-L
JF - EUR ARCH OTO-RHINO-L
SN - 0937-4477
IS - 11
M1 - 11
ER -